Positive Phase III Results Emerge for Remibrutinib in Chronic Spontaneous Urticaria Treatment

USA: In a significant development for patients suffering from chronic spontaneous urticaria (CSU), Novartis has released promising Phase III trial data confirming the sustained efficacy and long-term safety of oral remibrutinib as a potential treatment option. This breakthrough offers hope to individuals grappling with the debilitating symptoms of CSU, which include recurrent hives and severe itching, by providing a novel therapeutic approach.

In the pivotal Phase III studies, REMIX-1 and REMIX-2, treatment with remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, showed significant symptom improvement early, which sustained up to Week 52 in CSU patients who remained symptomatic despite second-generation H1-antihistamine use.
These findings were presented at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, May 31–June.
“A large majority of people with CSU are living with uncontrolled and debilitating symptoms, often trying to manage the condition by cycling through antihistamines at higher doses with no lasting respite, impacting heavily on their day-to-day lives,” said Martin Metz, Professor of Dermatology, Charité – Universitätsmedizin Berlin, Germany.
“Remibrutinib has become an important investigational treatment for CSU as it blocks the BTK cascade and inhibits histamine release. These data show that remibrutinib has the potential to offer patients and physicians a well-tolerated oral treatment that provides early and lasting efficacy.”
The following were the key findings of the study:
· Significant improvements with remibrutinib versus placebo, as previously shown at Week 12, were confirmed at Week 24, including in weekly urticaria activity score (UAS7), weekly itch severity score (ISS7), and weekly hive severity score (HSS7).
· At Week 24, patients receiving placebo transitioned to remibrutinib; responses with remibrutinib were observed as early as the first week after switching and were sustained until the study’s end (28 weeks of treatment).
· Almost half of patients were completely free of itch and hives (UAS7=0) as assessed at Week 52.
Remibrutinib was well-tolerated and demonstrated a favorable and consistent safety profile up to 52 weeks, including balanced liver function tests versus placebo.
During the 24-week placebo-controlled period, adverse events (AEs), including severe AEs and treatment discontinuations due to AEs, were comparable between remibrutinib and placebo. In addition, there was no increase in exposure-adjusted rates with long-term treatment. Liver transaminase elevations were balanced across the remibrutinib and placebo treatment groups; all were transient, asymptomatic, and reversible. None of the severe AEs were related to study medication by investigators.
“Urticaria is a disease that significantly impacts patients’ quality of life and there is an urgent need for new treatment options,” said Angelika Jahreis, Global Head, Development, Immunology, Novartis.
“The 52-week REMIX-1 and REMIX-2 Phase III data are significant as many patients who had moderate to severe urticaria at study start were completely free of hives and itch after 52 weeks of treatment and remibrutinib continued to be well tolerated. These exciting long-term data will be submitted to global health authorities later this year.”
In addition to CSU, remibrutinib is being investigated in several other immune-mediated conditions, such as hidradenitis suppurativa, where it met its primary endpoint in a Phase II study. It is also investigated in food allergy, chronic inducible urticaria, and multiple sclerosis.
Novartis will submit remibrutinib for approval in CSU to global health authorities starting in H2 2024.

Powered by WPeMatico

Universal adhesive used in etch-and-rinse mode for posterior composite restorations equally effective in moist and wet dentin: Study

The universal adhesive used in the etch-and-rinse mode for posterior composite restorations is equally effective in moist and wet dentin suggests a study published in the Journal of Dentistry.

A study was done to evaluate the influence of dentin moisture on the clinical behavior of a universal adhesive on posterior teeth after 36 months of follow-up. Forty-five patients participated in this study. Following a split-mouth design, three operators placed 90 Class I/Class II restorations over moist dentin (MD) or dry (DD) (n = 45) with resin composite (Filtek Bulk Fill) and a universal adhesive used in the etch-and-rinse mode (Single Bond Universal). Each restoration was evaluated according to the FDI and USPHS criteria (postoperative sensitivity, fracture and retention, marginal staining, marginal adaptation, and recurrence of caries) at baseline and after 6-, 12-, and 36 months. For statistical analysis, Kruskal Wallis analysis of variance rank (α = 0.05) and Kaplan-Meier survival analysis were used. Results: No significant difference between groups was observed in each FDI criterion after 36 months of clinical evaluation (p > 0.05). The retention rates (confidence interval 95 %) were 97.37 % (86.5 – 99.5) for both MD and DD without significant difference between them (p > 0.05). Eight restorations (MD = 4; DD = 4) showed minimal marginal staining defects (p > 0.05). Two restorations were lost (MD = 1; DD = 1). Fifteen restorations (MD = 8; DD = 7) presented minor marginal discrepancies according to the FDI criteria (p > 0.05). The clinical performance of the universal adhesive when applied in etch-and-rinse mode was not influenced by dentin moisture in posterior bulk-fill composite restorations. The level of dentin moisture appears not to influence the clinical efficacy of a universal adhesive when applied using the etch-and-rinse technique in posterior composite resin restorations.

Reference:

Romina Ñaupari-Villasante, Camila Falconi-Páez, Andrea S. Castro, Mario F. Gutiérrez, Maria L. Mendez-Bauer, Paulina Aliaga, Andrés Dávila-Sánchez, Cesar Arrais, A Reis, Alessandro D. Loguercio. Clinical performance of posterior restorations using a universal adhesive over moist and dry dentin: A 36-month double-blind split-mouth randomized clinical trial. Journal of Dentistry.Volume 147, 2024, 105080, ISSN 0300-5712,

https://doi.org/10.1016/j.jdent.2024.105080.

(https://www.sciencedirect.com/science/article/pii/S0300571224002495)

Keywords:

universal, adhesive, etch-and-rinse, mode, posterior, composite, restorations, equally, effective, moist, wet dentin, study, Journal of Dentistry, Composite restoration; Dental bonding; Universal adhesive; Clinical longevity; Randomized clinical trial

Powered by WPeMatico

Primary-hypercholesterolemia may increase risk of hepatic complications in general population: Study

Researchers have found that hypobetalipoproteinemia (HBL), characterized by permanently low levels of low-density lipoprotein-cholesterol (LDL-C), significantly increases the risk of cirrhosis complications and primary liver cancer. A recent study was published in the Journal of Hepatology by Matthieu W. and colleagues.

While low LDL-C levels are known to reduce cardiovascular risk, the broader health implications remain contentious. In primary HBL, incidences of liver steatosis and cirrhosis have been occasionally reported. This study aimed to investigate the association between HBL and the risk of hepatic complications in the general population, specifically focusing on cirrhosis complications and primary liver cancer.

A cohort study was conducted using data from the French CONSTANCES cohort and the UK Biobank (UKBB) cohort. Participants with primary HBL (LDL-C <5th percentile for age and sex) were compared to those with normal LDL-C levels (40th-60th percentile). Those on lipid-lowering therapies were excluded. Incidence density ratios (IDRs) were calculated to compare follow-up events related to hepatic complications.

The study analyzed 34,653 participants from CONSTANCES and 94,666 from the UKBB, with median ages of 45 and 56 years, respectively. The mean LDL-C concentrations in the HBL group versus the control group were 71 mg/dl vs. 128 mg/dl in CONSTANCES and 86 mg/dl vs. 142 mg/dl in the UKBB, with follow-up durations of 5.0 and 11.5 years.

  • Incidence of Hepatic Complications: In CONSTANCES, the HBL group had an incidence of 0.32/1,000 person-years compared to 0.07/1,000 person-years in the control group (IDR = 4.50, 95% CI 1.91-10.6).

  • In the UKBB, the incidence was 0.69/1,000 person-years for the HBL group vs. 0.21/1,000 person-years for the control group (IDR = 3.27, 95% CI 2.63-4.06).

  • Independence from Classical Risk Factors: The increased risk of hepatic complications in the HBL group was independent of obesity, alcohol consumption, diabetes, and viral hepatitis, as shown in a 5-year landmark analysis excluding early events.

The study underscores the independent association between HBL and an increased risk of hepatic complications, including primary liver cancer. This risk persists even when classical risk factors for liver disease are accounted for. Sensitivity analyses using apolipoprotein-B levels and genetically defined HBL showed consistent results, further validating the findings.

HBL should be recognized as a significant independent risk factor for liver diseases, necessitating specific prevention and screening strategies. Given the marked risk of hepatic complications in HBL patients, regular liver monitoring is crucial. The findings from this study reveal a critical need for targeted health interventions and continuous liver monitoring in individuals with hypobetalipoproteinemia. This approach could mitigate the elevated risk of liver disease complications associated with this lipid disorder.

Reference:

Wargny, M., Goronflot, T., Rimbert, A., Boursier, J., Kab, S., Henny, J., Lainé, A., Leux, C., Smati, S., Hadjadj, S., Le May, C., Goldberg, M., Zins, M., & Cariou, B. (2024). Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population. Journal of Hepatology, 80(6), 846–857. https://doi.org/10.1016/j.jhep.2024.01.030

Powered by WPeMatico

Can acupuncture reduce hot flashes and other side effects of anti-hormonal breast cancer therapy?

In a pooled analysis of three clinical trials, acupuncture significantly reduced hot flashes and other hormonal side effects of endocrine therapy taken by women with breast cancer. The analysis of data from the United States, China, and South Korea is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Endocrine therapy, which blocks hormone signaling that drives some forms of breast cancer, can be a life-saving treatment, but up to 80% of patients who take it experience hot flashes-a sudden, temporary sensation of body warmth, flushing, and sweating-and other side effects. Many patients who experience these symptoms discontinue endocrine therapy, which can put them at an elevated risk of cancer progression and death.

Other medications can reduce hot flashes, but they come with their own unpleasant side effects. Studies have evaluated the impact of acupuncture on hot flashes in women with early breast cancer undergoing endocrine therapy, with mixed results.

To provide more information about acupuncture’s potential, investigators conducted a coordinated, multinational project consisting of three independent randomized controlled trials in the United States, China, and South Korea that used the same eligibility criteria, acupuncture protocol, and study measures.

A total of 158 women with stage 0–III breast cancer were randomized to immediate acupuncture (IA) or delayed acupuncture control (DAC). IA participants received acupuncture twice a week for 10 weeks and were followed for an additional 10 weeks without acupuncture. DAC participants received usual care for 10 weeks, then crossed over to acupuncture with a reduced intensity (once per week) for 10 weeks. Standardized clinical questionnaires were used to assess hormonal symptoms—including hot flashes, night sweats, vaginal dryness, and joint pain-as well as quality of life related to physical well-being, functional well-being, emotional well-being, and social/family well-being.

At week 10 from the start of the trials, IA participants’ questionnaire scores reflected significant lessening of symptoms compared with DAC participants. Responses indicated that 64% of people in the IA group reported improvements in the number and severity of their hot flashes, compared with 18% in the DAC group. IA participants also reported greater improvements in quality of life compared with DAC participants.

Between week 10 and week 20, scores did not change significantly for IA participants. DAC participants who received weekly acupuncture during this time had significant improvements in symptom scores relative to week 10. There were no acupuncture-related side effects reported by any of the participants.

“By managing side effects, our approach makes it easier for patients to continue their prescribed medication, which has the potential to reduce the risk of cancer recurrence and improve long-term outcomes for breast cancer survivors,” said lead author Weidong Lu, MB, MPH, PhD, of the Dana-Farber Cancer Institute. “In practice, patients interested in using acupuncture for this purpose might begin with a short trial period to assess their response to the treatment, particularly in terms of reduction in hot flashes and other symptoms. If the trial period yields positive results, patients may then engage in a long-term program, receiving regular acupuncture sessions throughout the duration of their anti-hormonal medication regimen.”

Reference:

Weidong Lu, Anita Giobbie-Hurder,  Anna Tanasijevic , Sylvia Baedorf Kassis, Sung Hwan Park, Young Ju Jeong , Im Hee Shin , Chang Yao, Hyun Jung Jung KMD, Zhiyuan Zhu, Chao Bao, Ting Bao, EunMee Yang, LicAc, Barbara E. Bierer, Jennifer A. Ligibel, Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials, Cancer, https://doi.org/10.1002/cncr.35374.

Powered by WPeMatico

Hypoxemia due to sleep apnea associated with risk of lung cancer reoccurrence: Study

A new study to be presented at the SLEEP 2024 annual meeting is the first to find that episodic hypoxemia and hypoxic burden related to obstructive sleep apnea are associated with the risk of accelerated lung cancer reoccurrence.

Results show that a 4% oxygen desaturation index of more than 15 and time spent in desaturation events were risk factors for cancer reappearance in less than two years. Measures of hypoxic burden such as time spent below 89% oxygen saturation, average oxygen saturation value below 89%, and single nadir oxygen levels, showed a similar association. After adjustment for potential confounders, average oxygen saturation below 89% and single minimum oxygen level remained strongly correlated with accelerated cancer reoccurrence.

“We were suspecting that we would find a positive association between measures of intermittent hypoxemia and lung cancer reoccurrence; nonetheless, we never expected to see such a strong signal,” said lead author Dr. Fernando Figueroa Rodriguez, sleep medicine fellow at the Mayo Clinic in the division of pulmonary, critical care, and sleep medicine in Rochester, Minnesota. “This caught us by surprise; but at the same time, this keeps us encouraged and eager to produce more data.”

The study involved a retrospective record review of 403 adult patients from January 2016 to September 2023. They had a median age of 74 years, and 52% were female. The patients had a history of non-small cell lung cancer and received an overnight oximetry study within three years prior to undergoing curative malignancy treatment. During the study period, 68 patients (22%) had lung cancer reoccurrence, with a median time period of 19 months.

Figueroa Rodriguez noted that a new study with an increased sample size has been initiated for the performance of additional analyses to better understand this relationship. Similarly, researchers at the Mayo Clinic are evaluating the impact of CPAP therapy for sleep apnea on cancer outcomes.

“At this time we have not finalized these next steps; nevertheless, we have a fantastic team working on the necessary requirements to have this data ready soon,” said Figueroa Rodriguez.

Reference:

Fernando Figueroa Rodriguez, Kaiser Lim, Tobias Peikert, Patricio Escalante, Timothy Morgenthaler, 0468 CRASH: Cancer Reoccurrence Is Accelerated by Episodic Hypoxemia, Sleep, Volume 47, Issue Supplement_1, May 2024, Pages A201–A202, https://doi.org/10.1093/sleep/zsae067.0468.

Powered by WPeMatico

Is there a link between increased headaches and hotter temperatures for individuals with migraines?

As temperatures rise, so do chances for migraine attacks, according to a new study from a team of researchers at the University of Cincinnati College of Medicine, Icahn School of Medicine at Mount Sinai, Errex Inc. and Teva Pharmaceuticals USA. Inc.

“Weather change is one of the most common trigger factors for migraine,” says Vincent Martin, MD, director of the Headache and Facial Pain Center at UC’s Gardner Neuroscience Institute and UC Health physician. He is the study’s lead author and president of the National Headache Foundation.

These findings from the study, which looked at use of Fremanezumab and whether it could prevent headaches caused by temperature increases, will be presented at the American Headache Society’s 66th Annual Scientific Meeting, June 13-16 in San Diego, California.

Produced by Teva Pharmaceuticals USA. Inc., Fremanezumab is sold under the brand name AJOVY®, administered by injection under the skin, and is part of a set of monoclonal antibodies that have hit the market in the past six years to treat migraine in patients. This class of drugs blocks a protein known as CGRP (calcitonin gene-related peptide) which is responsible for transmission of pain in the brain and nervous system.

Researchers cross-referenced 71,030 daily diary records of 660 migraine patients with regional weather data and found that for every temperature increase of 10 degrees Fahrenheit daily, there was a 6% increase in occurrence of any headache. However, during the time periods of Fremanezumab treatment the association completely disappeared.

“This study is the first to suggest that migraine specific therapies that block CGRP may treat weather associated headaches,” says Fred Cohen, a study co-author and assistant professor of medicine at Icahn School of Medicine at Mount Sinai in New York, NY.

Martin adds that if the results are confirmed in future studies the drug therapy has the potential to help many people with weather triggered migraine.

“What we found was that increases in temperature were a significant factor in migraine occurrence across all regions of the United States,” says Martin, also a professor within UC’s College of Medicine. “It’s pretty amazing because you think of all the varying weather patterns that occur across the entire country that we’re able to find one that is so significant.”

Al Peterlin, who retired as chief meteorologist at the U.S. Department of Agriculture and co-author of the study, added another thought.

“Hippocrates, the father of medicine, believed that weather and medicine were intimately linked,” he says. “A couple thousand of years later, we are proving that weather matters in human health.”

Reference:

Is there a link between increased headaches and hotter temperatures for individuals with migraines?, University of Cincinnati, Meeting: 66th Annual Scientific Meeting of the American Headache Society.

Powered by WPeMatico

NEET Counselling for this academic year to begin on July 6 to fill 9703 MBBS, 2,270 BDS seats in UP

Uttar Pradesh- MBBS and BDS counselling is going to begin on July 6, 2024, for this academic year. The complete schedule of round-wise UP MBBS and BDS counselling is yet to be released.

Uttar Pradesh will begin its counselling process for undergraduate seats of MBBS and BDS courses from said date and the process will be conducted to fill 9703 MBBS seats and 2,270 BDS seats in UP. Only those candidates who have qualified for NEET and are included in the UP NEET merit list 2024 will be eligible to participate in the UP NEET counselling 2024 session for admission under 85% of state quota seats. With this, preparations for the counselling process have been done as per the existing guidelines of the National Testing Agency (NTA) and the National Medical Commission (NMC).

Medical Dialogues had earlier reported that there are altogether 704 medical colleges in India with an intake capacity of 1,07,948 MBBS seats, the Union Minister of State for Health and Family Welfare, Dr. Bharati Pravin Pawar stated in a written reply in the Lok Sabha. As per the data, there are 68 medical colleges in Uttar Pradesh with 9703 MBBS seats.

Speaking to the TOI on the NEET counselling, state NEET coordinator Avni Kamal said that usually around 7 lakh students apply for the counselling process.

In addition, a senior official of the Directorate of Medical Education (DME) informed that the verification of the candidates’ documents will be done at 20 centres across UP.

UP NEET counselling 2024 will be done on the basis of marks obtained by the candidates in the National Eligibility-Entrance Test, NEET 2024 exam. To participate in the UP MBBS/BDS counselling 2024 process, candidates have to follow the document verification process.

Given below is the list of documents required for verification during UP state NEET counselling-

1 Domicile certificate (to fulfil the eligibility criteria)

2 NEET 2024 hall tickets.

3 Caste certificate, if applicable.

4 NEET 2024 result.

5 Two passport-size photographs.

UP MBBS/BDS admission 2024 will be conducted in a total of three rounds including a mop-up round. During UP NEET 2024 counselling seat allotment, candidates have to fill in their preference of the colleges they want admission to. In that choice-filling session, candidates can select as many colleges as they want for the UP MBBS/BDS allotment process. Based on the choices filled by the candidate, availability of seats, NEET 2024 All India Rank, reservation criteria and various other factors, admission to UP MBBS 2024 will be granted.

Powered by WPeMatico

Will develop robust system with zero error, engage with students to understand concerns: Centre’s panel amid raging row over NEET

New Delhi: Amid a raging row over the alleged NEET UG 2024 paper leak controversy and the cancellation of other exams, former ISRO chief R Radhakrishnan heading a seven-member panel appointed by the government announced on Monday that they will engage with parents and students to understand their concerns and challenges about the examination process.

In its first meeting on Monday evening, Radhakrishnan told reporters on Tuesday as quoted by PTI “The first priority for us is to elicit from the students and parents in the country their concerns and suggestions. We are going to engage with them as far as possible in person, or through electronic media. And in the next fortnight, we would like to consolidate this.”

“The next priority for us is to quickly build a robust system for starting the tests. We are also looking at the future, especially to develop in this country a robust system, a tamper-proof system, a system with zero error and a system that will lessen the difficulties and stress for the students with adequate flexibility built into it,” he added.

Also read- NEET 2024 Paper Leak Case: CBI Collects All Material Evidence From Bihar Police, FIR Registered

According to sources present in the meeting, the committee took stock of the current situation and challenges faced by the National Testing Agency (NTA).

“The panel was apprised of the current processes and functioning of the agency. The panel also looked into the statistics provided by the NTA about the multiple exams conducted by it and the number of candidates appearing for each exam,” a source said.

“The panel also looked into which exams are conducted in pen and paper mode and which are conducted as Computer-Based Tests (CBT), and the nuances of both modes,” the source added.

During its meeting, the committee is also believed to have discussed cybersecurity issues and challenges posed by the darknet, where the UGC-NET exam question paper was first leaked forcing the Education Ministry to cancel it the day after it was conducted.

According to ministry officials, the reforms suggested by the panel are likely to be implemented by the next exam cycle.

“It is a mammoth task and has to be done with complete preparation to ensure there are no loopholes but it is also the most important priority of the ministry right now. The panel will submit its report within two months and we will draw an action plan to implement the reforms by the next exam cycle,” an official said on the condition of anonymity.

In the line of fire over the alleged irregularities in medical entrance examination NEET and PhD entrance NET, the Centre had on Saturday notified the panel to ensure transparent, smooth and fair conduct of examinations through the NTA.

While NEET is under scanner over several irregularities, including alleged leaks, UGC-NET was cancelled as the ministry received inputs that the integrity of the exam was compromised. Two other exams — CSIR-UGC NET and NEET PG — were cancelled as a pre-emptive step.

The panel will make recommendations on reforms in the mechanism of the examination process, improvement in data security protocols and the structure and functioning of the NTA.

The panel also includes former AIIMS Delhi director Randeep Guleria, Central University of Hyderabad Vice-Chancellor B J Rao, Professor Emeritus in the Department of Civil Engineering at IIT Madras K Ramamurthy, People Strong co-founder and Karmayogi Bharat board member Pankaj Bansal, IIT Delhi Dean of Student Affairs Aditya Mittal and Ministry of Education Joint Secretary Govind Jaiswal.

The committee has also been tasked with examining the existing security protocols related to the setting of the papers and other processes for different examinations and making recommendations to enhance the robustness of the system.

This year’s National Eligibility-and-Entrance Test Undergraduate (NEET-UG) 2024 Examination was mired in controversies after the allegations of paper leak came into light. Around 13 people, including four examinees and their family members, were arrested in Bihar for their alleged involvement in the paper leak of the NEET-UG exam. Patna police sources had previously claimed that the NEET-UG question papers along with their answers were provided to around 20 aspirants a day before the date of the exam i.e. May 5, 2024.

Then, the Economic Offences Unit (EOU) of Bihar Police, which took over the investigation, revealed that the brokers involved in the NEET paper leak scam took between Rs 30 lakh to Rs 50 lakh from each of the medical aspirants in exchange for giving them the question paper of the NEET UG 2024 question paper ahead of the examination.

Multiple pleas have been filed before the High Courts and the Supreme Court seeking an investigation into the alleged paper leak scam. Some of the pleas demanded the scrapping of the NEET UG 2024 exam and holding a retest.

Meanwhile, NEET aspirants across the country have been protesting against the alleged paper leak issue in NEET UG 2024 and the National Testing Agency’s policy of awarding grace marks to 1563 candidates. While finally the NTA decided to scrap the grace marks, the issue of alleged paper leak is still unsolved.

Although earlier, the Union Education Minister Dharmendra Pradhan had denied such allegations of paper leak, recently he assured action against NTA officials if they were found guilty of the “irregularities” in the conduct of the MBBS entrance exam.

The NEET 2024 issue has now taken a political turn as opposition parties are accusing the government over the allegations of rigging, paper leaks, and corruption. Recently Congress leader Rahul Gandhi argued that the BJP-ruled states were the “epicentre of paper leak”.

While hearing pleas concerning the NEET examination, the apex court had on June 18 said that even if there was “0.001 per cent negligence” on the part of anyone in the conduct of the examination, it should be thoroughly dealt with.

The Apex Court had also sought responses from the Centre and the NTA on a plea for a Central Bureau of Investigation (CBI) probe into allegations of question paper leak and other irregularities in the exam.

Also read- ‘Govt Has Nothing To Hide’, Says Chirag Paswan Over NEET Row

Powered by WPeMatico

Lower back pain can be reduced by walking 30 mins a day: Lancet

In a groundbreaking study, researchers have discovered that walking for just 30 minutes daily can significantly reduce low back pain. This world-first trial, aimed at assessing the effectiveness of low-cost exercise, offers new hope for those suffering from this common condition.
The trial involved 701 individuals across Australia, with an average age of 54, who had recently recovered from non-specific low back pain. Participants were randomly divided into two groups: an intervention group and a no-treatment control group. The intervention group engaged in progressive walking for at least 30 minutes daily for six months under the supervision of a trained physiotherapist. Both groups were followed for 12 to 36 months.

Reference:

Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack): a randomised controlled trial, Natasha C Pocovi, Prof Chung-Wei Christine Lin, Prof Simon D French, Petra L Graham, Johanna M van Dongen, Prof Jane Latimer, PhD, DOI:https://doi.org/10.1016/S0140-6736(24)00755-4

Powered by WPeMatico

BAMS doctor conducts delivery instead of a gynaecologist, patient dies of Postpartum Haemorrhage

A BAMS (Bachelor of Ayurvedic Medicine and Surgery) doctor allegedly conducted delivery of a 31-year-old patient at a private nursing home, in Patiala instead of a gynaecologist following which the patient is reported to have died from postpartum haemorrhage on Thursday night.
As per the latest HT report, the patient was experiencing excessive bleeding following the delivery, and despite the efforts of the BAMS doctor to manage the bleeding, he was unsuccessful. Consequently, she was transferred to Rajindra Hospital, where she tragically passed away moments later.
For more information, click on the link below:

Powered by WPeMatico